Diaceutics PLC (LON:DXRX) Insider Graham Paterson Purchases 11,643 Shares

Diaceutics PLC (LON:DXRX) insider Graham Paterson acquired 11,643 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were bought at an average cost of GBX 138 ($1.71) per share, with a total value of £16,067.34 ($19,912.43).

Diaceutics Trading Down 0.5 %

Shares of LON DXRX opened at GBX 136.25 ($1.69) on Friday. Diaceutics PLC has a twelve month low of GBX 92.24 ($1.14) and a twelve month high of GBX 151 ($1.87). The stock has a market cap of £115.09 million, a price-to-earnings ratio of -4,541.67 and a beta of 0.58. The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 2.93. The company’s fifty day moving average is GBX 129.87 and its 200-day moving average is GBX 128.56.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Canaccord Genuity Group restated a “buy” rating and set a GBX 160 ($1.98) target price on shares of Diaceutics in a report on Tuesday, December 17th. Canaccord Genuity Group reiterated a “buy” rating and issued a GBX 160 ($1.98) price target on shares of Diaceutics in a research report on Tuesday, December 17th.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.